James Cassella - Concert Pharmaceuticals Senior Vice President chief development officer
| CNCEDelisted Stock | USD 8.37 0.01 0.12% |
President
Dr. James V. Cassella Ph.D., is the Chief Development Officer of Concert Pharmaceuticals Inc, since February 2015. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from June 2004 to July 2012. From April 1989 to April 2004, Dr. Cassella held various management positions at Neurogen Corporationrationration, a publicly traded biotechnology company. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College since 2015.
| Age | 68 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Phone | 781 860 0045 |
| Web | https://www.concertpharma.com |
Concert Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3853) % which means that it has lost $0.3853 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0868) %, meaning that it created substantial loss on money invested by shareholders. Concert Pharmaceuticals' management efficiency ratios could be used to measure how well Concert Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Concert Pharmaceuticals currently holds 14.51 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Concert Pharmaceuticals has a current ratio of 9.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Concert Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Todd Gray | Old Republic International | 51 | |
| Bryan Petrucelli | Kinsale Capital Group | 58 | |
| Stephen CFA | Sun Life Financial | 60 | |
| Matt Bisig | Old Republic International | N/A | |
| Colm Freyne | Sun Life Financial | N/A | |
| Spencer LeRoy | Old Republic International | 74 | |
| Phillip Schutt | Old Republic International | 63 | |
| Cheryl Jones | Old Republic International | 70 | |
| Jacques Goulet | Sun Life Financial | 58 | |
| Frank Sodaro | Old Republic International | 52 | |
| Brian Haney | Kinsale Capital Group | 54 | |
| Daniel Fishbein | Sun Life Financial | N/A | |
| Diane Schnupp | Kinsale Capital Group | 57 | |
| Craig Smiddy | Old Republic International | 60 | |
| Mark Bilbrey | Old Republic International | 71 | |
| Mark Saunders | Sun Life Financial | N/A | |
| Helena Pagano | Sun Life Financial | N/A | |
| William Gray | Old Republic International | 56 | |
| Laura Money | Sun Life Financial | N/A | |
| Kevin Strain | Sun Life Financial | 54 | |
| Charles Boone | Old Republic International | 65 | |
Management Performance
| Return On Equity | -1.09 | |||
| Return On Asset | -0.39 |
Concert Pharmaceuticals Leadership Team
Elected by the shareholders, the Concert Pharmaceuticals' board of directors comprises two types of representatives: Concert Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Concert. The board's role is to monitor Concert Pharmaceuticals' management team and ensure that shareholders' interests are well served. Concert Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Concert Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nancy Stuart, Chief Officer | ||
| James Cassella, Senior Vice President chief development officer | ||
| Marc Becker, Chief Officer | ||
| Christine Boisclair, Vice President - Regulatory Affairs | ||
| Justine Koenigsberg, VP of Corporate Communications and Investor Relations | ||
| Jeffrey Munsie, Chief Sec | ||
| Nabil PharmD, VP Devel | ||
| Roger Tung, Co-Founder, CEO and President and Director | ||
| Mba MBA, CoFounder Chairman |
Concert Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Concert Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (2.88) % | |||
| Current Valuation | 86.63 M | |||
| Shares Outstanding | 48.02 M | |||
| Shares Owned By Insiders | 3.77 % | |||
| Shares Owned By Institutions | 77.05 % | |||
| Number Of Shares Shorted | 1.08 M | |||
| Price To Earning | 3.08 X | |||
| Price To Book | 1.67 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Concert Stock
If you are still planning to invest in Concert Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Concert Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |